Cloris Xue

发表

Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS

C. Ryerson, M. Kolb, J. Swigris, 2020, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, The Lancet. Oncology.

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.

G. Long, Yibing Yan, A. Menzies, 2022, European journal of cancer.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, Journal of Clinical Oncology.

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer

K. Jerzak, C. Brezden-Masley, Cloris Xue, 2020, Breast Cancer Research and Treatment.

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer

K. Jerzak, C. Brezden-Masley, Cloris Xue, 2020, Breast Cancer Research and Treatment.

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

K. Jerzak, C. Brezden-Masley, Cloris Xue, 2020, Cancer medicine.

First‐line atezolizumab monotherapy in patients with advanced BRAFV600 wild‐type melanoma

A. C. de Melo, A. Wainstein, I. Caro, 2021, Pigment cell & melanoma research.

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

P. Fasching, A. Bardia, Yeon-Hee Park, 2022, Journal of Clinical Oncology.

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies

G. Barteselli, I. Caro, G. Goodman, 2022, Drug Safety.

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.

A. Bardia, Yeon-Hee Park, D. Yardley, 2023, The Lancet. Oncology.